Kite, a Gilead Company, a biopharmaceutical company based in Santa Monica, has leased a building in the Netherlands to produce its gene-based cancer therapies in Europe, the company announced May 15.
The firm leased the 117,000-square-foot site in Hoofddorp to manufacture and deliver its personalized CAR-T cancer-fighting treatments.
The plant, expected to provide 300 jobs, is expected to open in 2020.
Gilead Sciences purchased Kite Pharma Inc. last summer for $11.9 billion. It then won federal approval for Kite’s personalized immunotherapy for adults with non-Hodgkin’s lymphoma.
In January, the Kite subsidiary paid $135 million to buy a 160,000 square-foot biotech laboratory once run by Agensys Inc. in Santa Monica to conduct cell therapy research, development and expansion.
It has also leased a 26,000 square-foot facility in Gaithersburg, Md., to work with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Kite Adds Production in Europe
- European Regulators Give an Early Nod to Cancer Treatments From Puma, Kite
- Kite Wins Approval to Market Cancer Therapy in Europe
- Kite Will Pay up to $3 Billion for Experimental Cancer Therapy
- Gilead Sciences and Kite Pharma Acquire Cell Design Labs
- Kite Sells $40M in Cellular Blood Cancer Treatments
- Feds Give Kite Pharma’s Cancer Treatment the Green Light
- Kite Wins Approval to Sell Blood Cancer Treatment in the U.K.